article thumbnail

WCG Announces Partnership with Mint Medical to Support Imaging in Oncology Clinical Trials

WCG Clinical

Princeton, NJ, June 28, 2023 — WCG, one of the world’s leading providers of solutions that measurably improve the quality, efficiency, and safety of clinical research, recently announced a partnership with Mint Medical to leverage its mint Lesion™ radiology platform for oncology trials. in New Jersey, USA.

article thumbnail

Integration of AI in imaging clinical trials 

Drug Discovery World

Sophie Winandy , Executive Director of Medical Imaging at ICON explores the benefits of AI and how it can be integrated throughout medical imaging within clinical trials. These advances are seen in many indications of imaging as it relates to drug trials – oncological, cardiovascular, metabolic, NASH, musculoskeletal and other.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pilot and Feasibility Testing: The LIRE Example

Rethinking Clinical Trials

Jerry Jarvik, principal investigator of the LIRE Demonstration Project, discusses pilot and feasibility testing in pragmatic clinical trials.

Radiology 130
article thumbnail

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. Dr. Bahassi: There are several factors to consider when designing a trial that involves ctDNA detection.

article thumbnail

FDA approves Phase III cerebral Adrenoleukodystrophy trial

Drug Discovery World

The US Food and Drug Administration (FDA) has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD).

article thumbnail

Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery

The Pharma Data

The Phase II SBIR grant is a follow-on 2–year award that will support testing of Alume’s fluorescent nerve targeting agent in an ongoing Phase 1/2 clinical trial in patients undergoing Head and Neck Surgery. About Alume Biosciences, Inc. To learn more about Alume, visit www.alumebiosciences.com.

article thumbnail

Why I Fight | A message from Gary Fishbein, MD, MPH

Worldwide Clinical Trials

Join us as we celebrate cancer research awareness month and clinical trials awareness month. Where I trained at the University of Maryland, there was literally a bridge that connected the research labs to the clinic. As I think back to my time in college, I was very interested in the rights of human subjects on research trials.